Xuanzhu Biopharmaceutical Co., Ltd. is an international research and development (R&D) enterprise of innovative drugs. Founded in 2002 with the registered capital of 100 million yuan,Xuanzhu Biopharm is focused on R&D of new chemical entities. It is a wholly-owned subsidiary and innovative drug research institute of Sihuan Pharmaceutical Holdings Group Ltd (Sihuan Pharma). Sihuan Pharma, listed in Hong Kong (stock code: 00460.HK) on October 28, 2010, has developed into a multi-functional pharmaceutical group company, covering R&D, manufacture and corresponding sales. We work on seven cutting-edge therapeutic areas, such as antibiotics, cardiovascular diseases, oncology and diabetes. So far, multiple technology platforms have been established, including New Drug Design and Synthesis Center, Center for Pharmacology, Center for Drug Metabolism and Pharmacokinetics, Center for Early Safety Assessment & Research, API Scale-Up Center, Formulation R&D Center. Besides, a complete system of new drug R&D has been set up, covering a wide spectrum from structure design of new drug to drug screening and evaluation for CRCD, from IND application to new drug application. Xuanzhu Biopharm has been in a leading position in the field of new drug discovery and development in China and is committed to building a world-class innovative drug research platform.